Table 1.
Summary of included studies
| Studya | N | Intervention versus control | Study design | Follow-up (months) | Age (years) | Male sex (%) | De novo MM (%) | Previous CKDb (%) | Chemotherapy regimen intervention/ control |
|---|---|---|---|---|---|---|---|---|---|
| Hutchison et al. [20] (2019, UK, Germany) | 90 | HCO-HD versus HF-HD | RCT | 24 | 65.5 | 57 | 100 | 4.4 | BTZ + DOX + DEX/ BTZ + DOX + DEX |
| Bridoux et al. [19] (2017, France) | 98 | HCO-HD versus HF-HD | RCT | 48 | 68.8 | 55 | 100 | 11.7 | BTZ + DEX/BTZ + DEX |
| Gerth et al. [25] (2016, Germany) | 59 | HCO-HD versus HF-HD | Retrospective cohort | 12 | 63.1 | 50.8 | 54 | 27.1 | Novel agentsc 76.2%/novel agents 23.5% |
| Curti et al. [24] (2016, Switzerland) | 19 | HCO-HD versus HF-HD | Retrospective cohort | 72.7 | 63.0 | 73,7 | 83 | NR | BTZ + DEX/BTZ + DEXd |
| Peters et al. [23] (2011, France) | 10 | HCO-HD versus HD | Retrospective cohort | 12.9 | 71 | 50 | 100 | NR | BTZ + DEX/BTZ + DEX or DEX + MPT or DEX |
DOX, doxorubicin; DEX, dexamethasone; MPT, melphalan; NR, not reported.
a
Year of publication and setting (country or region) provided in parentheses.
b
CKD is defined as an estimated glomerular filtration rate ≤30 mL/min/1.73 m2.
c
BTZ, thalidomide or lenalidomide.
d
Other additional chemotherapy agents were administered to some patients.